Bio-Techne (NASDAQ:TECH) was downgraded by BidaskClub from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday.

A number of other analysts have also issued reports on TECH. Deutsche Bank raised their price target on Bio-Techne from $130.00 to $132.00 and gave the stock a “buy” rating in a research note on Wednesday, August 9th. Zacks Investment Research lowered Bio-Techne from a “buy” rating to a “hold” rating in a research note on Tuesday, August 15th. Finally, Citigroup reissued a “buy” rating and issued a $115.00 price target (down from $125.00) on shares of Bio-Techne in a research note on Tuesday, October 24th. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $134.33.

Shares of Bio-Techne (TECH) opened at $128.72 on Tuesday. The company has a quick ratio of 2.25, a current ratio of 2.87 and a debt-to-equity ratio of 0.35. Bio-Techne has a 52 week low of $95.68 and a 52 week high of $136.39. The stock has a market capitalization of $4,862.97, a PE ratio of 37.41, a price-to-earnings-growth ratio of 3.24 and a beta of 0.75.

Bio-Techne (NASDAQ:TECH) last issued its quarterly earnings results on Tuesday, October 31st. The biotechnology company reported $0.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.82 by $0.08. Bio-Techne had a return on equity of 14.11% and a net margin of 12.54%. The firm had revenue of $144.61 million for the quarter, compared to analyst estimates of $142.37 million. During the same period last year, the company earned $0.84 EPS. The firm’s quarterly revenue was up 10.7% on a year-over-year basis. equities analysts predict that Bio-Techne will post 3.76 earnings per share for the current year.

In other news, Director Robert V. Baumgartner sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $130.18, for a total value of $650,900.00. Following the transaction, the director now directly owns 12,712 shares in the company, valued at approximately $1,654,848.16. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last 90 days, insiders sold 5,200 shares of company stock worth $675,190. Company insiders own 3.40% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in TECH. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Bio-Techne by 12.6% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,456 shares of the biotechnology company’s stock worth $171,000 after purchasing an additional 163 shares during the period. Zions Bancorporation purchased a new stake in shares of Bio-Techne during the 3rd quarter valued at about $178,000. Flinton Capital Management LLC raised its holdings in shares of Bio-Techne by 84.8% during the 2nd quarter. Flinton Capital Management LLC now owns 1,952 shares of the biotechnology company’s stock valued at $229,000 after buying an additional 896 shares during the period. Turner Investments LLC purchased a new stake in shares of Bio-Techne during the 3rd quarter valued at about $242,000. Finally, Koch Industries Inc. purchased a new stake in shares of Bio-Techne during the 2nd quarter valued at about $286,000. Institutional investors own 97.03% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://theolympiareport.com/2017/12/07/bio-techne-tech-rating-lowered-to-hold-at-bidaskclub.html.

Bio-Techne Company Profile

Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world.

Analyst Recommendations for Bio-Techne (NASDAQ:TECH)

Receive News & Ratings for Bio-Techne Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.